Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19
Jean M. Connors, Maria M. Brooks, Frank C. Sciurba, et al.
JAMA (2021) Vol. 326, Iss. 17, pp. 1703-1703
Open Access | Times Cited: 220

Showing 1-25 of 220 citing articles:

Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus
Betty Raman, David A. Bluemke, Thomas F. Lüscher, et al.
European Heart Journal (2022) Vol. 43, Iss. 11, pp. 1157-1172
Open Access | Times Cited: 526
Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 382
Understanding COVID-19-associated coagulopathy
Edward M. Conway, Nigel Mackman, Ronald Q. Warren, et al.
Nature reviews. Immunology (2022) Vol. 22, Iss. 10, pp. 639-649
Open Access | Times Cited: 246
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
Carolyn T. Bramante, Jared D. Huling, Christopher J. Tignanelli, et al.
New England Journal of Medicine (2022) Vol. 387, Iss. 7, pp. 599-610
Open Access | Times Cited: 203
ISTH guidelines for antithrombotic treatment in COVID‐19
Sam Schulman, Michelle Sholzberg, Alex C. Spyropoulos, et al.
Journal of Thrombosis and Haemostasis (2022) Vol. 20, Iss. 10, pp. 2214-2225
Open Access | Times Cited: 145
Therapeutic advances in COVID-19
Naoka Murakami, Robert Hayden, Thomas Hills, et al.
Nature Reviews Nephrology (2022) Vol. 19, Iss. 1, pp. 38-52
Open Access | Times Cited: 128
Clinical and Genetic Risk Factors for Acute Incident Venous Thromboembolism in Ambulatory Patients With COVID-19
Junqing Xie, Albert Prats‐Uribe, Qi Feng, et al.
JAMA Internal Medicine (2022) Vol. 182, Iss. 10, pp. 1063-1063
Open Access | Times Cited: 71
Mechanisms of long COVID and the path toward therapeutics
Michael J. Peluso, Steven G. Deeks
Cell (2024)
Open Access | Times Cited: 23
From ICU Syndromes to ICU Subphenotypes: Consensus Report and Recommendations For Developing Precision Medicine in ICU
Anthony Gordon, Narges Alipanah, Lieuwe D. J. Bos, et al.
American Journal of Respiratory and Critical Care Medicine (2024) Vol. 210, Iss. 2, pp. 155-166
Open Access | Times Cited: 19
2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19
Sam Schulman, Donald M. Arnold, Charlotte Bradbury, et al.
Journal of Thrombosis and Haemostasis (2024) Vol. 22, Iss. 6, pp. 1779-1797
Open Access | Times Cited: 18
Barriers and facilitators to conducting human subjects research at a safety net institution from the perspective of researchers
Sandra D. Barnes, Yewon Na, Mari‐Lynn Drainoni, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0313530-e0313530
Open Access | Times Cited: 1
Anticoagulation and Antiplatelet Therapy for Prevention of Venous and Arterial Thrombotic Events in Critically Ill Patients With COVID-19: COVID-PACT
Erin A. Bohula, David D. Berg, Mathew S. Lopes, et al.
Circulation (2022) Vol. 146, Iss. 18, pp. 1344-1356
Open Access | Times Cited: 65
A multisystem, cardio-renal investigation of post-COVID-19 illness
Andrew Morrow, Robert Sykes, Alasdair McIntosh, et al.
Nature Medicine (2022) Vol. 28, Iss. 6, pp. 1303-1313
Open Access | Times Cited: 64
Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper
Thomas Marjot, Christiane S. Eberhardt, Tobias Boettler, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 4, pp. 1161-1197
Open Access | Times Cited: 62
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum
Geoffrey D. Barnes, Allison Burnett, Arthur L. Allen, et al.
Journal of Thrombosis and Thrombolysis (2022) Vol. 54, Iss. 2, pp. 197-210
Open Access | Times Cited: 54
Association of Early Aspirin Use With In-Hospital Mortality in Patients With Moderate COVID-19
Jonathan H. Chow, Ali Rahnavard, Mardi Gomberg‐Maitland, et al.
JAMA Network Open (2022) Vol. 5, Iss. 3, pp. e223890-e223890
Open Access | Times Cited: 52
Anticoagulation in Patients With COVID-19
Michael E. Farkouh, Gregg W. Stone, Anuradha Lala, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 9, pp. 917-928
Open Access | Times Cited: 51
Thromboprophylactic low-molecular-weight heparin versus standard of care in unvaccinated, at-risk outpatients with COVID-19 (ETHIC): an open-label, multicentre, randomised, controlled, phase 3b trial
Frank Cools, Saverio Virdone, J.P.S. Sawhney, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 8, pp. e594-e604
Open Access | Times Cited: 51
Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial
Stefano Barco, Davide Voci, Ulrike Held, et al.
The Lancet Haematology (2022) Vol. 9, Iss. 8, pp. e585-e593
Open Access | Times Cited: 48
Platelets and SARS-CoV-2 During COVID-19: Immunity, Thrombosis, and Beyond
Anthony R. Sciaudone, Heather A. Corkrey, Fiachra Humphries, et al.
Circulation Research (2023) Vol. 132, Iss. 10, pp. 1272-1289
Open Access | Times Cited: 38
Appropriate thromboprophylaxis strategy for COVID-19 patients on dosage, antiplatelet therapy, outpatient and post-discharge prophylaxis: a meta-analysis of randomized controlled trials
Jiahao Meng, Hang Tang, Yifan Xiao, et al.
International Journal of Surgery (2024)
Open Access | Times Cited: 8
COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type
James R. Hilser, N. Sṕencer, Kimia Moeeni Afshari, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2024) Vol. 44, Iss. 11, pp. 2321-2333
Closed Access | Times Cited: 7
Good practice statements for antithrombotic therapy in the management of COVID‐19: Guidance from the SSC of the ISTH
Alex C. Spyropoulos, Jean M. Connors, James D. Douketis, et al.
Journal of Thrombosis and Haemostasis (2022) Vol. 20, Iss. 10, pp. 2226-2236
Open Access | Times Cited: 36
COVID-19 Coagulopathy: From Pathogenesis to Treatment
Teba Alnima, Mark M. G. Mulder, Bas C.T. van Bussel, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 282-296
Open Access | Times Cited: 30
Platelet Activation and Thrombosis in COVID-19
Toshiaki Iba, Hideo Wada, Jerrold H. Levy
Seminars in Thrombosis and Hemostasis (2022) Vol. 49, Iss. 01, pp. 055-061
Closed Access | Times Cited: 30
Page 1 - Next Page

Scroll to top